<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129331">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01764776</url>
  </required_header>
  <id_info>
    <org_study_id>CLDE225A2113</org_study_id>
    <nct_id>NCT01764776</nct_id>
  </id_info>
  <brief_title>Effect of Hepatic Impairment on LDE225..</brief_title>
  <official_title>A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects
      with impaired hepatic function and healthy subjects with normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>LDE225A pharmacokinetic parameter Tmax</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDE225A pharmacokinetic parameter Cmax</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDE225A pharmacokinetic parameter AUClast</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDE225A pharmacokinetic parameter AUCinf</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDE225A pharmacokinetic parameter  T1/2</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of abnormal safety laboratory parameters</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma protein binding of LDE225</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma protein binding of LDE225</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of changes in ECGs</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ECGs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of  adverse event</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>follow up on any adverse event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Normal Hepatic Function,</condition>
  <condition>Impaired Hepatic Function</condition>
  <arm_group>
    <arm_group_label>LDE225</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDE225</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE225</intervention_name>
    <description>LDE225</description>
    <arm_group_label>LDE225</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all groups):

          -  Male and sterile or postmenopausal female age ≥18 to ≤70 years old.

          -  Normal Vital signs

        Inclusion (group mild, moderate and severe hepatic impairment):

        -Subjects with confirmed cirrhosis

        Exclusion (all groups):

          -  Woman of childbearing potential and pregnant or lactating females or male not using
             condom

          -  Risk factors for torsades de pointes

          -  Clinically significant cardio-vascular disease

          -  severe or uncontrolled medical conditions

          -  Smokers consuming greater than 10 cigarettes or equivalent nicotine containing
             products per day.

          -  Use of investigational drugs (i.e. participation in any clinical investigation)

        Exclusion for moderate, mild and severe groups:

          -  Symptoms or history of encephalopathy

          -  Clinical evidence of severe ascites

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami Div. of Clinical Pharmacology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-243-5930</phone>
    </contact>
    <investigator>
      <last_name>Richard A. Preston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Troitsk</city>
        <state>Russia</state>
        <zip>142190</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDE225,</keyword>
  <keyword>Pharmacokinetics,</keyword>
  <keyword>PK,</keyword>
  <keyword>Postmenopausal women,</keyword>
  <keyword>normal hepatic function,</keyword>
  <keyword>mild hepatic impairment,</keyword>
  <keyword>moderate hepatic impairment,</keyword>
  <keyword>severe hepatic impairment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
